Vicente Iii Valero

Q: What Schools Are Affiliated With Vicente Iii Valero

Vicente Iii Valero is affiliated with the following schools: Université libre de Bruxelles, MD Anderson Cancer Center, University of Alberta, University of Newcastle , Cairo University, Istanbul University, University of California, Los Angeles, Stanford University, Johns Hopkins University, University of Washington, Comenius University, Okayama University, University of Naples Federico II

Vicente Iii Valero's AcademicInfluence.com Rankings

Vicente Iii Valero

Philosophy

#6481

World Rank

#9523

Historical Rank

Logic

#3637

World Rank

#4828

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Vicente Iii Valero's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Vicente Iii Valero Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vicente Iii Valero's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adjuvant trastuzumab in HER2-positive breast cancer. (2011) (1199)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (2007) (1171)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. (2008) (993)
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009) (829)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. (2006) (714)
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. (2005) (667)
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. (2009) (628)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. (2001) (577)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013) (576)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. (2002) (571)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. (2006) (561)
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. (2004) (556)
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. (2011) (528)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. (2008) (518)
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. (2009) (426)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. (2005) (400)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. (1995) (385)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017) (383)
Adjuvant Trastuzumab in HER 2-Positive Breast Cancer (2011) (383)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. (2005) (369)
Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. (2006) (366)
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. (2003) (358)
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. (2006) (349)
Minority cancer patients and their providers (2000) (340)
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2011) (302)
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. (2005) (288)
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. (2004) (287)
Docetaxel for treatment of solid tumours: a systematic review of clinical data. (2005) (280)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (2018) (269)
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. (2004) (259)
Genomic index of sensitivity to endocrine therapy for breast cancer. (2010) (257)
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. (2007) (249)
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. (1999) (247)
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. (2014) (237)
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. (2012) (221)
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. (2003) (218)
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. (1998) (213)
Breast cancer metastasis: challenges and opportunities. (2009) (213)
Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. (2006) (212)
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. (2007) (211)
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment (2011) (210)
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system (2012) (207)
Positive surgical margins and ipsilateral breast tumor recurrence predict disease‐specific survival after breast‐conserving therapy (2003) (205)
Cancer pain management among underserved minority outpatients (2002) (205)
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors (2010) (203)
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. (2010) (201)
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. (2001) (200)
Biphasic metaplastic sarcomatoid carcinoma of the breast. (2006) (192)
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. (2005) (191)
Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer (2010) (190)
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes (2014) (188)
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. (2009) (186)
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. (2001) (185)
Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer (2012) (183)
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study (2016) (183)
Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors (2014) (177)
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. (2007) (176)
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. (2002) (175)
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. (1996) (173)
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. (2000) (169)
Female patients with breast carcinoma age 30 years and younger have a poor prognosis (2001) (165)
Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. (2006) (163)
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. (2011) (163)
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. (2001) (157)
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer (2010) (155)
Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women (2008) (155)
Mammary angiosarcomas: imaging findings in 24 patients. (2007) (154)
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma (2006) (144)
Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy (2003) (144)
Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy: A Model for Performance Evaluation (2016) (143)
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. (2009) (142)
Inflammatory breast cancer (IBC) and patterns of recurrence (2007) (142)
A randomized trial of minoxidil in chemotherapy-induced alopecia. (1996) (139)
Primary angiosarcomas of the breast (2007) (135)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery (2017) (133)
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. (2011) (133)
Inflammatory breast cancer: what we know and what we need to learn. (2012) (129)
Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer (2009) (129)
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. (2001) (129)
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer (2000) (128)
Circulating tumor cells in metastatic breast cancer (2008) (128)
Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma (2016) (127)
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab (2017) (127)
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy (2017) (124)
A Management Algorithm and Practical Oncoplastic Surgical Techniques for Repairing Partial Mastectomy Defects (2008) (123)
Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group (2017) (118)
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. (2005) (118)
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. (2014) (117)
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers (2012) (116)
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. (2010) (115)
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination (2014) (112)
Squamous cell carcinoma of the breast. (2005) (112)
Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer (2011) (112)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (111)
Efficacy of Anastrozole in Male Breast Cancer (2002) (111)
Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. (2006) (111)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study (2019) (110)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. (2020) (110)
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early (2011) (108)
Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. (2007) (107)
The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy (2016) (107)
Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an unusual case. (1986) (105)
Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer (2008) (105)
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. (2012) (105)
Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy (2017) (105)
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials (2016) (105)
Risks and Benefits of Taxanes in Breast and Ovarian Cancer (2000) (103)
Docetaxel secretion in tears: association with lacrimal drainage obstruction. (2002) (103)
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. (2005) (102)
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells (2011) (102)
Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (102)
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial (2012) (98)
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. (2014) (98)
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. (2012) (97)
Pain education for underserved minority cancer patients: a randomized controlled trial. (2004) (97)
Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer (2002) (97)
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. (2008) (96)
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. (2001) (95)
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. (2011) (93)
Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer (2016) (92)
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. (2015) (92)
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. (2002) (92)
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. (2016) (91)
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. (2011) (91)
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. (2012) (90)
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. (2003) (85)
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. (2010) (84)
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. (2010) (83)
Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy (2017) (81)
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. (1999) (81)
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. (2005) (81)
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis (2015) (80)
Imaging differences in metaplastic and invasive ductal carcinomas of the breast. (2007) (80)
High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer (2014) (80)
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy (2003) (78)
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients (2016) (77)
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. (2005) (75)
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. (2014) (74)
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma (2001) (73)
Outcomes of children exposed in utero to chemotherapy for breast cancer (2014) (71)
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference (2018) (71)
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer (2016) (71)
Characterization of long non‐coding RNA transcriptome in clear‐cell renal cell carcinoma by next‐generation deep sequencing (2015) (71)
Metaplastic Sarcomatoid Carcinoma of the Breast With Absent or Minimal Overt Invasive Carcinomatous Component: A Misnomer (2005) (70)
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. (2004) (68)
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. (2008) (68)
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. (2017) (68)
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. (2007) (67)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients (2021) (67)
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome (2011) (67)
Breast cancer multifocality and multicentricity and locoregional recurrence. (2013) (67)
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. (2016) (66)
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? (2003) (66)
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. (2002) (65)
Disease‐free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy (2006) (64)
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity (2017) (64)
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms (2014) (63)
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer (2008) (63)
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations (2017) (62)
A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients with Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy: 3-Year Follow-Up (2011) (62)
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. (2015) (61)
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. (2002) (61)
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer (2002) (61)
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. (2010) (61)
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer (2011) (60)
Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis (2015) (60)
Leptomeningeal disease and breast cancer: the importance of tumor subtype (2014) (59)
Clinical Course of Breast Cancer Patients With Metastases Limited to the Liver Treated With Chemotherapy (2008) (59)
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. (1997) (59)
Combined‐modality treatment for isolated recurrences of breast carcinoma (2005) (59)
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. (2015) (58)
p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer (2004) (58)
MELD-XI Score Predicts Early Mortality in Patients After Heart Transplantation. (2015) (57)
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy (2018) (57)
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. (2001) (56)
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. (1993) (56)
Management of perihilar cholangiocarcinoma in the era of multimodal therapy (2012) (55)
Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer (2008) (55)
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. (2002) (54)
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers (2011) (53)
Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer (2003) (52)
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. (2002) (51)
Hand‐foot syndrome following prolonged infusion of high doses of vinorelbine (1998) (51)
Identifying factors that impact survival among women with inflammatory breast cancer. (2012) (51)
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer (2018) (50)
Multifocality and multicentricity in breast cancer and survival outcomes. (2012) (50)
Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. (2015) (50)
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. (2003) (50)
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients (2009) (49)
A nonreplicating adenoviral vector that contains the wild‐type p53 transgene combined with chemotherapy for primary breast cancer (2006) (48)
Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. (2016) (47)
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity (2017) (47)
Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. (2006) (46)
Circulating tumor cells in newly diagnosed inflammatory breast cancer (2015) (46)
Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy (2004) (46)
A unified definition of clinical anthracycline resistance breast cancer (2000) (46)
Tamoxifen Increases the Risk of Microvascular Flap Complications in Patients Undergoing Microvascular Breast Reconstruction (2012) (45)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (2016) (44)
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. (2005) (44)
Emerging targeted therapies for breast cancer. (2010) (44)
The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. (2019) (43)
Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy: A Multi-institutional Analysis and External Validation (2017) (43)
A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2008) (42)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer (2012) (41)
Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy (2004) (41)
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer (2016) (41)
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer (2002) (41)
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (2021) (41)
A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. (2011) (41)
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. (2001) (39)
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy (2000) (39)
Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission. (2015) (39)
Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. (2020) (39)
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. (2012) (39)
Epidemiological risk factors associated with inflammatory breast cancer subtypes (2016) (38)
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer (2014) (38)
USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer (2013) (37)
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. (2002) (37)
The impact of paravertebral block analgesia on breast cancer survival after surgery (2016) (37)
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. (2012) (37)
HER‐2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger (2005) (36)
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors (2016) (35)
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (2018) (35)
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer (2007) (35)
The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy (2005) (34)
High incidence of germline BRCA mutation in patients with ER low‐positive/PR low‐positive/HER‐2 neu negative tumors (2015) (34)
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. (1998) (34)
Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer (2010) (34)
Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy (2015) (33)
Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials (2007) (33)
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations (2013) (33)
Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer (2019) (33)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. (2011) (33)
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. (1995) (33)
Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials (2005) (33)
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. (2004) (32)
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. (2015) (32)
Capecitabine‐Induced Pancreatitis (2003) (32)
Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma (2006) (32)
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. (2015) (31)
Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. (2007) (31)
Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents (2014) (31)
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. (2017) (31)
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (2011) (31)
BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). (2006) (31)
Primary soft tissue sarcoma of the breast (2001) (31)
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. (2015) (30)
Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer (2014) (30)
What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis (2004) (30)
Emerging role of Hpo signaling and YAP in hepatocellular carcinoma (2015) (30)
Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women: Kesson EM, Allardice GM, George WD, et al (Gartnavel Royal Hosp, Glasgow, UK; Western Infirmary, Glasgow, UK; et al) BMJ 344:e2718, 2012§ (2012) (29)
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. (2019) (29)
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. (2007) (29)
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. (2001) (29)
Circulating tumor cells in metastatic inflammatory breast cancer. (2009) (28)
Mesenteric laceration complicating a Heimlich maneuver. (1986) (28)
Incidence of and survival following brain metastases among women with inflammatory breast cancer. (2010) (27)
Pathologic complete response in breast cancer patients receiving anthracycline‐ and taxane‐based neoadjuvant chemotherapy (2010) (27)
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy (2015) (27)
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. (2020) (27)
A novel risk score that incorporates recipient and donor variables to predict 1-year mortality in the current era of lung transplantation. (2015) (27)
Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (2011) (27)
Prognostic significance of occult axillary lymph node metastases after chemotherapy‐induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer (2009) (26)
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer (2012) (26)
Identification of frequent somatic mutations in inflammatory breast cancer (2017) (26)
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome (2010) (26)
A novel risk scoring system reliably predicts readmission after pancreatectomy. (2015) (26)
Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) (2020) (26)
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer (2017) (25)
Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma (1999) (25)
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. (2012) (25)
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer (2012) (25)
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. (1995) (25)
Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction (2016) (25)
Survival and Functional Status After Bridge-to-Transplant with a Left Ventricular Assist Device. (2019) (25)
A risk score to predict acute renal failure in adult patients after lung transplantation. (2015) (24)
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. (2017) (24)
Risk factors for falls in older patients with cancer (2017) (24)
Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer (2014) (24)
Preoperative performance status impacts perioperative morbidity and mortality after lung transplantation. (2015) (24)
What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? (2004) (24)
Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. (2006) (23)
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines (2018) (23)
A Phase II study of intravenous exatecan mesylate (DX‐8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (2003) (23)
A randomized phase 2 trial comparing 3‐hour versus 96‐hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer (2010) (23)
Automated pain intervention for underserved minority women with breast cancer (2015) (23)
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. (2011) (23)
Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions (2017) (23)
Current Status of Clinical Trials with Paclitaxel and Docetaxel (1994) (22)
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study (2019) (22)
Stability of estrogen receptor status in breast carcinoma: A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy (2011) (22)
Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). (2010) (22)
Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. (2016) (21)
Multifocality and multicentricity in breast cancer and survival outcomes. (2012) (21)
LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) (2017) (21)
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma (2013) (21)
Outcomes in patients with early‐stage breast cancer who underwent a 21‐gene expression assay (2017) (21)
Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies (2017) (21)
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. (1999) (20)
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation (2016) (20)
Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer (2016) (20)
Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. (1998) (20)
Genotype–Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers (2015) (20)
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy (2015) (20)
Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma (2013) (20)
Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. (2009) (20)
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy (2000) (19)
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy (2020) (19)
Genomic of circulating tumor cells in metastatic breast cancer (2007) (19)
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. (2018) (19)
Surgical indications and optimization of patients for resectable esophageal malignancies. (2014) (18)
A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer (2004) (18)
A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative (2014) (17)
Malnutrition and overall survival in older patients with cancer. (2018) (17)
Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen (2004) (17)
Overall survival in older patients with cancer (2018) (17)
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy (2019) (17)
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. (2015) (17)
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer (2016) (16)
Tamoxifen-Induced Female Androgenetic Alopecia in a Patient with Breast Cancer (1997) (16)
Paclitaxel-induced pancreatitis: a case report. (1997) (16)
Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer (2004) (16)
Phase II study of deoxyspergualin in metastatic breast cancer (2004) (16)
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. (2022) (16)
Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. (2013) (15)
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. (1997) (15)
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment (2019) (15)
Phase II study of taxotere in refractory metastatic breast cancer (RMBC) (1993) (15)
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer (2018) (15)
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. (2016) (15)
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer (2015) (15)
Neurocognitive deficits in older patients with cancer. (2018) (15)
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer (2018) (15)
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer (2020) (14)
Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer (2002) (14)
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation (2017) (14)
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger (2008) (14)
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy (2015) (14)
Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center (2018) (14)
Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience (2018) (14)
Primary chemotherapy with docetaxel for the management of breast cancer. (2002) (13)
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. (1994) (13)
Measuring Briefing and Checklist Compliance in Surgery (2014) (13)
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. (2003) (13)
Women age ≤ 35 years with primary breast carcinoma (2005) (13)
Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2009) (13)
Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. (2018) (13)
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases (2014) (13)
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. (1997) (12)
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1) (2019) (12)
The influence of institutional volume on the incidence of complications and their effect on mortality after heart transplantation. (2015) (12)
Docetaxel and cyclophosphamide in patients with advanced solid tumors. (1997) (12)
Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis (2020) (12)
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy. (2021) (12)
Analysis of Fcγ Receptor IIA & IIIA Polymorphisms: Correlation with Outcome in Trastuzumab-Treated HER2/Neu Amplified Early and Metastatic Breast Cancer Patients. (2009) (12)
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. (2021) (12)
A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma (2003) (12)
Factors associated with improved outcomes for metastatic inflammatory breast cancer patients (2018) (11)
Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. (2018) (11)
Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. (2020) (11)
Bisphosphonates and pathologic complete response to taxane‐ and anthracycline‐based neoadjuvant chemotherapy in patients with breast cancer (2012) (11)
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. (2012) (11)
Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma (2001) (11)
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer (2019) (11)
Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? (2013) (10)
Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. (2010) (10)
Primary chemotherapy: a better overall therapeutic option for patients with breast cancer. (1998) (10)
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer (2010) (10)
Liver abscess complicating Crohn's disease presenting as thoracic empyema. Case report and review of the literature. (1985) (10)
Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. (2005) (10)
Ixabepilone for the treatment of breast cancer (2011) (10)
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer (2021) (10)
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β (2018) (9)
Update on systemic treatment for newly diagnosed inflammatory breast cancer (2020) (9)
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) (2021) (9)
A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. (2006) (9)
MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells (2011) (9)
Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). (2012) (9)
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. (2008) (9)
Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. (2015) (9)
Neoadjuvant Pertuzumab‐containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER‐2/neu‐positive Breast Cancer: A Retrospective, Single Institution Experience (2018) (9)
Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC) (2010) (9)
2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) (2007) (9)
Characterization of Metastatic Breast Cancer Patients with Non-Detectable Circulating Tumor Cells. (2009) (9)
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. (1998) (8)
Future direction of neoadjuvant therapy for breast cancer. (1998) (8)
Metastasis in the breast mimicking inflammatory breast cancer. (2012) (8)
Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients (2010) (8)
Development of CNS metastases and survival in patients with inflammatory breast cancer (2018) (8)
Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. (2015) (8)
Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) (2013) (8)
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. (2017) (8)
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience (1999) (8)
Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results. (2006) (7)
Second-line chemotherapy for metastatic breast cancer including quality of life issues (1996) (7)
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. (2020) (7)
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC) (2020) (7)
Prognostic Factors for Invasive Breast Cancer (1999) (7)
Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation (2001) (7)
Paclitaxel-induced sickle cell crisis. (2008) (7)
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple‐negative breast cancer (2021) (7)
Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy (2003) (7)
Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. (2004) (7)
Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. (2011) (6)
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. (2010) (6)
Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048). (2010) (6)
Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carbopl (2011) (6)
Treatment of patients resistant to paclitaxel therapy (1996) (6)
The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer (2021) (6)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (2015) (6)
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer (2006) (6)
The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. (2021) (6)
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. (2015) (6)
Trastuzumab(T) (Herceptin) - associated cardiomyopathy: sequential stress and response to ace-inhibitors and carvedilol therapy (2003) (6)
Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. (2016) (6)
Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? (2017) (6)
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. (1998) (6)
Comparison of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaTest breast cancer for detection and biological characterization (2008) (5)
LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). (2015) (5)
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. (2022) (5)
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (2013) (5)
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (5)
Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. (2020) (5)
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (2011) (5)
The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. (2010) (5)
Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics (2009) (5)
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. (2019) (5)
Managing ixabepilone adverse events with dose reduction. (2013) (5)
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations (2020) (5)
Molecular profiling using breast cancer subtype to plan for breast reconstruction. (2017) (5)
Clinical Aspect of Inflammatory Breast Cancer: Diagnosis, Criteria, Controversy (2012) (5)
Inflammatory Breast Cancer: Clinical Features and the Role of Multimodality Therapy (1996) (5)
MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. (2022) (4)
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. (2000) (4)
Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories. (2009) (4)
Carboplatin for early triple-negative breast cancer? (2014) (4)
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. (2009) (4)
Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma (2005) (4)
Clinical course of 771 patients with bilateral breast cancer (BBC): Characteristics associated with overall and recurrence-free survival (2007) (4)
Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study (2022) (4)
Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy (2007) (4)
Abstract P5-16-30: Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy (2017) (4)
Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. (2016) (4)
Randomized trial of Tibetan yoga in breast cancer patients undergoing chemotherapy. (2014) (4)
Phase II study of weekly docetaxel (Taxotere; txt) and trastuzumab (Herceptin; H) for patients with HER-2 overexpressing (HER2+) metastatic breast cancer (MBC) (2001) (4)
Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. (2006) (4)
Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer (2011) (4)
Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay. (2016) (4)
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. (2017) (4)
Sentinel lymph node dissection is technically feasible in older breast cancer patients. (2010) (4)
Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer. (2009) (4)
Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. (2004) (4)
Survival of patients with breast cancer tumors 1 cm or less. Analysis of the Surveillance, Epidemiology and End Results (SEER) Registry (2005) (4)
Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. (2022) (4)
Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer (2021) (4)
Sarcomatoid (metaplastic) carcinoma of the breast: The U.T. M.D. Anderson Cancer Center (MDACC) and SEER database experience (2005) (4)
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. (2021) (3)
Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer (2008) (3)
Prognostic significance of geriatric assessment. (2017) (3)
P53 alterations show significant correlation with gene amplification and s-phase index in breast-cancer. (1995) (3)
Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature (2014) (3)
Abstract P1-17-01: Differences in Survival among Women with Stage III Inflammatory and Non-Inflammatory Locally Advanced Breast Cancer Appear Early: A Large Population Based Study (2010) (3)
Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. (2014) (3)
High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study. (2019) (3)
Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). (2021) (3)
Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. (2021) (3)
Abstract OT1-1-16: A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC) (2015) (3)
Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients. (2022) (3)
Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. (2009) (3)
Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation (2003) (3)
TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer. (2018) (3)
Predictive Value of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Patients Treated by Bevacizumab-Based Therapy. (2009) (3)
Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) (2020) (3)
Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers (2008) (3)
Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. (2017) (2)
HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials. (2016) (2)
Abstract PD04-02: Clinical Value of Circulating Tumor Cells (CTC) in First Line Metastatic Breast Cancer (MBC) Patients (pts) According to Type of Treatment and Immunohistochemical Molecular Subtype (2010) (2)
Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study (2020) (2)
Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab (2016) (2)
Impact of 21-gene RT-PCR assay on adjuvant therapy for stage I breast cancer. (2014) (2)
Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC). (2016) (2)
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer (2020) (2)
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. (2015) (2)
Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer (2005) (2)
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. (2020) (2)
Taxanes in metastatic breast cancer patients with impaired liver function (2005) (2)
Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. (2012) (2)
Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma (2002) (2)
Abstract P4-01-04: Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients (2015) (2)
Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy (2017) (2)
Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy. (2013) (2)
Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). (2018) (2)
Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. (2013) (2)
Abstract P3-06-02: The use of imaging and tumor markers in the staging of patients age <65 years with early-stage breast cancer (2013) (2)
Abstract P3-09-12: Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory breast cancer (mIBC) and non-IBC triple negative breast cancer (mTNBC) (2020) (2)
Racial and Ethnic Disparities in Breast Cancer: A Collaboration Between the American College of Radiology Commissions on Women and Diversity and Breast Imaging (2021) (2)
Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC) (2019) (2)
Breast Cancer Subtype and Baseline Characteristics from Diabetic Breast Cancer Patients are Not Different from Nondiabetics (2014) (2)
Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (2022) (2)
Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race. (2010) (2)
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. (2020) (2)
Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers (2008) (2)
Abstract P5-15-02: The benefit of targeted therapeutics in medical oncology since the development of trastuzumab (2012) (2)
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice (2020) (2)
Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer (2005) (2)
ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer (2021) (2)
Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule (2009) (2)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience (2004) (2)
Abstract P3-12-06: Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy (2013) (2)
Identification of Docetaxel in Tears from Patients with Metastatic Breast Cancer (2002) (2)
Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer (2013) (2)
Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts). (2012) (2)
Abstract P1-14-04: A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2 (2016) (1)
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases (2021) (1)
P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry. (2011) (1)
Neoadjuvant Therapy of Breast Cancer (2006) (1)
Abstract P5-14-08: Prospective phase II study of concurrent capecitabine and radiation demonstrates futility in triple negative chemo-resistant breast cancer (2013) (1)
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice (2020) (1)
Effect of targeted therapy on circulating tumor cells in patients with metastatic breast cancer. (2012) (1)
Breast Cancer in Identical Twins with Different Clinical Course (1996) (1)
Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer (2008) (1)
Systemic and Targeted Therapy (2012) (1)
Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer (2017) (1)
Abstract P6-12-02: Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer (2013) (1)
Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients. (2013) (1)
MELD-XI Score Predicts Early and Late Mortality in Patients Following Heart Transplantation (2015) (1)
Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy (2018) (1)
Abstract P3-02-03: Prognostic Value of Circulating Tumor Cells (CTC) in HER-2 Positive Metastatic Breast Cancer (MBC) Patients (pts) Treated with Anti-HER2-Based Therapy (2010) (1)
Abstract PS4-05: Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC) (2021) (1)
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). (2021) (1)
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. (2019) (1)
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer (2022) (1)
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer (2014) (1)
Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. (2006) (1)
Resection of liver metastases from breast cancer: Effect of timing of surgery and estrogen receptor status on outcome. (2011) (1)
Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer. (2009) (1)
Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab (2016) (1)
Patient controlled methyphenidate [PCM] for cancer-related fatigue [CRF]: A randomized controlled trial (2005) (1)
Systemic therapy for patients with breast cancer and one to three brain metastases (BM). (2020) (1)
Abstract CT076: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (1)
Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease (2016) (1)
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) (2022) (1)
Abstract P3-10-05: Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression. (2012) (1)
Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node‐Negative (T1a,bN0) Invasive Breast Cancer (2011) (1)
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review (2021) (1)
Circulating tumor cells (CTCs) in metastatic breast cancer: Biological value beyond tumor burden. (2006) (1)
Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (2015) (1)
Molecular Medicine in Practice Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer (2012) (1)
Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. (2009) (1)
Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer (2012) (1)
Performance Status Impacts Mortality Following Lung Transplantation (2014) (1)
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination (2014) (1)
Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999-2012. (2015) (1)
Abstract PD6-06: Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (1)
Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS) (2020) (1)
Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). (2010) (1)
Abstract OT1-03-04: INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC) (2019) (1)
Long term cardiac tolerability of trastuzumab in HER-2-overexpressing metastatic breast cancer (MBC). (2006) (1)
Impact of neoadjuvant chemotherapy to surgery interval on survival outcomes in breast cancer patients. (2015) (1)
Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger (2004) (1)
Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. (2009) (1)
191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) (2022) (1)
10-year outcomes of breast cancer patients with histologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. (2013) (1)
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. (2011) (1)
Cardiotoxicity of Anthracycline–Taxane Combinations in Metastatic Breast Cancer (2006) (1)
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple‐Negative Breast Cancer (2022) (1)
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases (2021) (1)
Chemotherapy of Metastatic Breast Cancer TAXANES : DRUGS OF THE 1990 S The introduction of paclitaxel ( Taxol ® (2001) (0)
A short-term biomarker modulation prevention study of anastrazole in women at increased risk for breast cancer. (2009) (0)
Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI (2023) (0)
Circulating tumor cells and risk of venous thromboembolism in metastatic breast cancer patients. (2016) (0)
An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer (2020) (0)
Impact of Regional Nodal Irradiation After Neoadjuvant Chemotherapy in Breast Cancer Patients With Cytologically Confirmed Axillary Lymph Node Metastases (2017) (0)
Abstract PD13-02: Site of recurrence after neoadjuvant therapy: A multi-center pooled analysis (2021) (0)
Phase I and pharmacokinetic (PK) study of oblimersen, a proapoptotic Bcl-2 targeting oligonucleotide, in combination with doxorubicin and docetaxel in metastatic and locally advanced breast cancer (BC). (2004) (0)
Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. (2011) (0)
Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC) (2023) (0)
Phase I I S tudy o f P egylated L iposomal D oxorubicin i n Combination W ith G emcitabine i n P atients W ith M etastatic Breast C ancer (2003) (0)
Brain Metastases in Women with Inflammatory Breast Cancer (IBC): Incidence, Treatment and Outcome. (2009) (0)
Targeted therapy for breast cancer (2011) (0)
Abstract P6-09-23: SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer (2017) (0)
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment (2019) (0)
Abstract P2-09-04: Development of novel combination therapy of IGF-1R/InsR and MEK inhibitors in triple-negative breast cancer (TNBC) (2013) (0)
Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-Generation Sequencing (2014) (0)
Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (0)
Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based chemotherapy. (2014) (0)
Abstract P5-20-13: Preliminary report of a phase I/II study of entinostat (IND#NSC 706995, /M275) and lapatinib (IND#NSC 727989) in patients with HER2-positive metastatic breast cancer in whom trastuzumab has failed (2012) (0)
Abstract OT3-2-05: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2015) (0)
Abstract P3-02-04: Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy (2023) (0)
Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer (2020) (0)
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. (2023) (0)
Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy (2019) (0)
Abstract OT2-03-03: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (0)
A randomized, double-blind, controlled trial of methylphenidate for fatigue in patients with advanced cancer. (2010) (0)
Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response (2016) (0)
Chfr methylation as a marker of taxane sensitivity in breast cancer. (2004) (0)
Abstract P6-14-06: Prospective Testing of Three Different Gene-Signatures for Patient Selection for Dasatinib Therapy in Metastatic Breast Cancer (2010) (0)
Abstract P6-02-10: Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients (2019) (0)
Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. (2023) (0)
TITLE-Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics Running title-Metaplastic breast cancer characterization (2009) (0)
Abstract P2-11-04: Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer (2020) (0)
Abstract P1-05-15: DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer (2023) (0)
Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer (2023) (0)
Triple-Negative/Basal Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer (2010) (0)
Abstract P6-01-06: Multi-Parametric MRI-Based Radiomics Models from Tumor and Peritumoral Regions as Potential Predictors of Treatment Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients (2023) (0)
Carcinosarcoma of the Breast (2012) (0)
Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. (2012) (0)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (0)
Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study (2005) (0)
Circulating tumor cells in newly diagnosed inflammatory breast cancer (2015) (0)
Clinical Cancer esearch ictive Biomarkers and Personalized Medicine luation of a 30-Gene Paclitaxel , Fluorouracil , Doxorubicin , Cyclophosphamide Chemotherapy Response Predictor R Multicenter Randomized Trial in Breast Cancer (2010) (0)
Outcomes in Patients Bridged With Univentricular and Biventricular Devices Prior to Heart Transplantation (2015) (0)
Abstract PS2-42: Identify breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment - an international, multicenter analysis (2021) (0)
Epithelial and mesenchymal circulating tumor cells as markers of survival and recurrence in pancreatic adenocarcinoma (2015) (0)
International E xpert P anel o n t he U se o f P rimary (Preoperative) S ystemic T reatment o f O perable B reast C ancer: Review a nd R ecommendations (2003) (0)
Abstract P5-20-02: Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC). (2012) (0)
Locoregional treatment outcomes for patients with ipsilateral supraclavicular metastases at diagnosis of breast cancer (2004) (0)
Internat ional Expert Panel on the Use of Pr imary ( Preoperat i ve ) Systemic Treatment of Operable Breast Cancer : Rev iew and Recommendat ions (2003) (0)
Predictors of Index Hospitalization Costs after Major Pancreatic Resection (2017) (0)
Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. (2015) (0)
P3-03-02: Higher Expression Levels of Circulating miR-21, miR-19a and miR-10b Are Associated with High Risk Features in Breast Cancer. (2011) (0)
Abstract OT2-3-10: Phase II study of panitumumab, nab-paclitaxel, and carboplatin for patients with primary inflammatory breast cancer (IBC) without HER2 overexpression (2012) (0)
Abstract P1-08-03: Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers (2022) (0)
Abstract P5-01-02: Quantitative assessment of tumor response to neoadjuvant chemotherapy in women with locoregional invasive breast cancer using Tc99m sestamibi molecular breast imaging - preliminary results (2018) (0)
Abstract 1796: A targeted RNA-seq assay to measure activating ER mutations and ER/PR-associated gene expression predicts sensitivity to endocrine therapy for metastatic breast cancer (2017) (0)
Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. (2014) (0)
Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy (2019) (0)
Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients (2019) (0)
Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. (2004) (0)
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (0)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience. (2004) (0)
Leptomeningeal disease and breast cancer: Relationship of outcome and subtype. (2013) (0)
Abstract OT1-1-15: A phase II study of dovitinib as salvage therapy in patients with stage IV inflammatory breast cancer HER2-negative with local or distant relapse (2015) (0)
Abstract P6-12-12: MiR-19a released by the triple negative inflammatory breast cancer SUM149 cells can be taken up by dendritic cells and induce increased synthesis of the proinflammatory cytokines IL-6 and TNF-a (2013) (0)
Mechanistic evaluation of the combination effect of paclitaxel (Pac) and bevacizumab (Bev) in breast cancer xenografts. (2009) (0)
Abstract 564: Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer (2018) (0)
A Novel Risk Score to Predict 1-Year Mortality Following Lung Transplant in the Current Era (2015) (0)
Abstract P5-06-10: Validation of prognostic stage and anatomic stage in the American joint committee on cancer 8th edition for inflammatory breast cancer (2020) (0)
P4-10-06: Evaluation of BRCAPro Risk Assessment Model in Patients with Ductal Carcinoma In Situ. (2011) (0)
Abstract P5-10-02: High serum levels of miR-19a are associated with poor outcome in metastatic inflammatory breast cancer (2012) (0)
Effect of Trastuzumab and Chemotherapy on Circulating Tumor Cells in Patients with Poor Prognosis Metastatic Breast Cancer. (2009) (0)
Abstract P3-11-02: Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience (2013) (0)
Abstract P1-08-08: Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer viamathematical modeling and quantitative MRI (2022) (0)
Epidemiological risk factors associated with inflammatory breast cancer subtypes (2016) (0)
Physicians’ attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study (2022) (0)
Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1 (2006) (0)
ression Patterns in Different Subtypes of Breast Cancer (2010) (0)
Baseline proliferation markers and cytopathologic findings in breast epithelium of women at increased risk for breast cancer (2005) (0)
Abstract P4-01-02: Circulating tumor cells detected after neoadjuvant therapy for inflammatory breast cancer are associated with early relapse despite pCR (2020) (0)
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. (2020) (0)
Epidemiologic Factors Associated with Inflammatory Breast Cancer - An Analysis of the Inflammatory Breast Cancer Registry at the University of Texas M.D. Anderson Cancer Center (2014) (0)
What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review. (2021) (0)
EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy. (2015) (0)
Abstract P3-17-05: Physicians’ attitudes and perceived barriers to adherence to national breast cancer clinical practice guidelines (BCCPG) in Mexico (2022) (0)
Abstract LB-314: Patients with inflammatory breast cancer have significant reductions in immune cells responsible for adaptive immunity (2010) (0)
Abstract P6-02-04: Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC) (2019) (0)
Institutional Volume Impacts Failure to Rescue Following Heart Transplantation (2015) (0)
Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence (2018) (0)
Abstract OT1-02-01: Pilot study of prognostic utility of circulating tumor cells (CTCs) assessed by AdnaGen technology and clinical outcome of patients with stage III breast cancer who completed locoregional and systemic treatment (2016) (0)
Microscopic disease after neoadjuvant therapy in inflammatory breast cancer. (2010) (0)
Breast conservation therapy in T4 locally advanced breast cancer: Effective local control with long-term survival (2004) (0)
Abstract P6-12-03: Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy (2013) (0)
Abstract P1-02-07: Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay (2017) (0)
Ginecologia y Obstetricia de Mexico (2010) (0)
Pretreatment Staging PET/CT in Patients with Inflammatory Breast Cancer Influences Radiation Treatment Field Designs (2011) (0)
Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. (2012) (0)
Long-term clinical outcome of patients with stage IIIc locally advanced breast cancer (2004) (0)
Abstract PD07-03: A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer (2010) (0)
Outcomes of children exposed in uteroto chemotherapy for breast cancer (2014) (0)
P4-07-10: Circulating Tumor Cells in Newly Diagnosed Inflammatory Breast Cancer. (2011) (0)
Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older breast cancer patients. (2013) (0)
Breast Cancer in Identical Twins with Different Clinical Course (1996) (0)
Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab /carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide (AC) for newly diagnosed primary triple-negative inflammatory breast cancer (TNIBC) (2018) (0)
A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC). (2013) (0)
Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression. (2010) (0)
Prevalence of vitamin D insufficiency and falls in older cancer patients. (2017) (0)
Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. (2017) (0)
Abstract PD6-07: Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (0)
Evaluation of the BRCAPRO model in a cohort of Hispanic families. (2006) (0)
Impact of chemotherapy and radiation therapy on local control and survival of metastatic breast cancer to the brain: Single-institution review of 792 cases. (2014) (0)
Molecular characterization of triple-negative breast cancers using gene expression profiling (2008) (0)
Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) (0)
Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC) (2023) (0)
Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. (2020) (0)
Abstract P6-14-07: High miR-19a serum levels correlate with favorable prognosis in patients with metastatic HER2+ inflammatory breast cancer and may result from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab (2015) (0)
Elevated serum levels of Sialyl Lewis X (sLeX) and inflammatory cytokines in patients with nonmetastatic breast cancer. (2011) (0)
Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients. (2011) (0)
Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). (2020) (0)
Survival outcome of breast cancer (BC) patients presenting with recurrent and de novo isolated contralateral lymph node metastases (CLNM). (2018) (0)
Textbook of Uncommon Cancer (2012) (0)
Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) (2023) (0)
Classification of molecular subtypes of triple-negative breast cancer using reverse phase protein arrays (RPPAs). (2014) (0)
Abstract P4-08-19: Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer (2023) (0)
Tissue Transglutaminase 2 as a Predictive and Prognostic Factor: A Pilot Study of Neoadjuvant Therapy in Women with Breast Cancer (2017) (0)
Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer (2001) (0)
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations (2013) (0)
Abstract P4-04-18: High serum miR-19a levels correlated with favorable prognosis in patients with metastatic HER2+ breast cancer and might result from effective antibody-dependent cell-mediated cytotoxicity (ADCC) induced by trastuzumab and Th1-mediated antitumor immune response (2016) (0)
Abstract P2-02-04: Circulating protein biomarker profile for inflammatory breast cancer using a multiplexed proximity extension assay (2018) (0)
Prospective E valuation o f P aclitaxel V ersus C ombination Chemotherapy W ith F luorouracil, D oxorubicin, and C yclophosphamide a s N eoadjuvant T herapy i n P atients With O perable B reast C ancer (1999) (0)
Patient interest in exploring nonsurgical treatment approaches for early-stage breast cancer: A qualitative study. (2022) (0)
Phase I a nd I I S tudy o f E xisulind i n C ombination W ith Capecitabine i n P atients W ith M etastatic B reast C ancer (2003) (0)
Abstract PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers (2013) (0)
Epidemiologic Factors Associated with Inflammatory Breast Cancer (2014) (0)
Circulating Tumor Cells and FDG-PET/CT for the Therapeutic Monitoring of Bone Metastases from Breast Cancer. (2009) (0)
Abstract P6-01-35: A Pre-operative Dynamic Contrast Enhanced MRI-Based Radiomics Models as Predictors of Treatment Response after Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients (2023) (0)
Abstract P3-09-05: Identification of optimal adjuvant chemotherapy regimen for early-stage breast cancer: A systematic review and bayesian network meta-analysis (2015) (0)
Addition of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to Trastuzumab Stabilizes Disease in Patients with Trastuzumab-Resistant, HER2+ Metastatic Breast Cancer. (2009) (0)
Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer. (2009) (0)
Abstract P3-02-04: Dendritic Cells from Breast Cancer Patients with ≥5 CTCs Are Functionally Impaired (2010) (0)
Abstract P4-01-10: Predictive impact of circulating tumor cells with an epithelial-to-mesenchymal transition phenotype in patients with primary breast cancer treated with primary systemic therapy (2015) (0)
Abstract PD11-07: Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer (2022) (0)
Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM). (2006) (0)
Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification (2001) (0)
Abstract P2-10-32: Sialyl LewisXand inflammatory mediators in breast cancer patients: biological correlations and prognostic value (2012) (0)
Clinical Outcomes in Two Different Cohorts of Patients with Inflammatory Breast Cancer (IBC) Treated at the MD Anderson Cancer Center: The Experience of the Morgan Welch IBC Research Program and Clinic. (2009) (0)
Angiosarcoma of the breast. (2006) (0)
1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC) (2015) (0)
Abstract P1-01-19: Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts (2017) (0)
Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment (2001) (0)
P4-20-04: Cytokine Synthesis by Activated Dendritic Cells in Relation to Disease Progression in Inflammatory Breast Cancer (IBC). (2011) (0)
Abstract PD3-11:HER2/ERBB2status in “HER2equivocal” breast cancers by FISH and ASCO-CAP guidelines: False-positives due to heterozygous deletions of alternative control loci (2019) (0)
Abstract P6-01-34: Longitudinal DCE-MRI Radiomic Models for Early Prediction of Response to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer (TNBC) Patients (2023) (0)
Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program (2023) (0)
Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort. (2020) (0)
Abstract OT2-07-09: A phase Ib study of neratinib, pertuzumab, and trastuzumab with paclitaxel in patients with metastatic and locally advanced breast cancer (2019) (0)
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI (2023) (0)
T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. (2016) (0)
Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway (2015) (0)
LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS (2019) (0)
Improved Outcomes Amongst High Risk Lung Transplant Patients at High Volume Centers: A Case for Regionalization in the US (2015) (0)
Abstract OT1-02-02: A pilot study to examine the feasibility of measuring CTC and inflammatory biomarker changes resulting from atorvastatin as adjuvant therapy in TNBC and TN-IBC patients with residual disease after neoadjuvant chemotherapy (2020) (0)
LOP09: Biomarkers in Breast Cancer as Preoperative Predictors of Adjuvant Radiation Treatment and Cancer Recurrence—The Dawn of Genomics in Plastic Surgery Practice (2014) (0)
Personalized Medicine and Imaging Gene Signature – Guided Dasatinib Therapy in Metastatic Breast Cancer (2014) (0)
Breast cancer multifocality-multicentricity and locoregional recurrance. (2012) (0)
Abstract P4-10-09: Relapse-free survival of triple negative breast cancer long term survivors and characterization of late events in MD Anderson experience (2016) (0)
The Role of Ultrasound of the Regional Nodal Basins in Staging Patients With Triple-Negative Breast Cancer: Implications for Local-Regional Treatment (2014) (0)
Abstract P1-11-22: Bisphosphonates and Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer (2010) (0)
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. (2023) (0)
Predictive and prognostic nomograms for breast cancer treated with primary chemotherapy (PC) (2005) (0)
972 Phase I study of cyclophosphamide and docetaxel (taxotere®) in solid tumors (1995) (0)
Abstract P1-17-02: Outcome after Locoregional Recurrence in Patients with Inflammatory Breast Cancer (2010) (0)
Prolonged Ischemia Does Not Affect Survival Following Lung Transplantation (2014) (0)
Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment. (2013) (0)
Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%). (2016) (0)
Abstract P5-15-03: Patient Characteristics and Clinical Outcome of Patients with Secondary Inflammatory Breast Cancer. M.D. Anderson Cancer Center, Retrospective Review (2010) (0)
EVALUATION OF LEISHMANIASIS DEVELOPMENT DURING A SHORT COURSE OF FTY720: 2330 (2008) (0)
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. (2022) (0)
Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing. (2014) (0)
PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (2014) (0)
Ef fi cacy of short-term psychodynamic psychotherapy ( STPP ) with depressed breast cancer patients : results of a randomized controlled multicenter trial (2014) (0)
Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer (2017) (0)
P4-20-03: T-Cell Cytokine Production Related to Progression of Breast Cancer Patients. (2011) (0)
Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation (2004) (0)
Breast cancer multifocality-multicentricity and survival outcomes. (2012) (0)
Abstract OT2-2-06: Phase II single arm study of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy (2015) (0)
139O SERUM HER-2/NEU DECLINE PREDICTS IMPROVED RESPONSE TO TRASTUZUMAB-BASED THERAPY (2006) (0)
Taxol in metastatic breast cancer the MD Anderson Cancer Center experience (1994) (0)
Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT) (2021) (0)
Phase I S tudy o f S tealth L iposomal D oxorubicin i n Combination W ith G emcitabine i n t he T reatment o f Patients W ith M etastatic B reast C ancer (2001) (0)
Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors 1 (2003) (0)
Abstract P3-02-07: Serum Angiogenic Factors but Not TGF-≥1 Are Positively Correlated with CTC in Metastatic Breast Cancer Patients (2010) (0)
Abstract 2736: Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin (2022) (0)
Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer (2015) (0)
Abstract PD04-03: Circulating Tumor Cells as Predictor of Metastatic Disease Spread in Patients with Breast Cancer (2010) (0)
Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. (2011) (0)
P1-02-07: Epithelial-Mesenchymal Transition Correlated with Serum Cytokine Profiling in Breast Cancer Patients. (2011) (0)
Differences in lung cancer symptom severity by tertiary cancer center vs. centers treating underserved patients (2007) (0)
Proteomic prediction in hormone receptor-positive breast cancer. (2006) (0)
Difference in outcomes among patients undergoing open versus laparoscopy-assisted approach for gastric cancer: A multi-institutional analysis. (2014) (0)
Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer. (2006) (0)
Abstract P5-19-22: A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer (2015) (0)
Abstract P6-03-09: Genetic polymorphism and correlation with treatment induced cardiotoxicity and prognosis inHER2amplified early breast cancer patients (2016) (0)
Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. (2015) (0)
Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients (2023) (0)
Cancer esearch or and Stem Cell Biology gnostic and Therapeutic Implications of Distinct Kinase R ression Patterns in Different Subtypes of Breast Cancer (2010) (0)
Abstract OT1-02-05: A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vicente Iii Valero?

Vicente Iii Valero is affiliated with the following schools:

Université libre de Bruxelles
MD Anderson Cancer Center
University of Alberta
University of Newcastle
Cairo University
Istanbul University
University of California, Los Angeles
Stanford University
Johns Hopkins University
University of Washington
Comenius University
Okayama University
University of Naples Federico II